Vamorolone

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Edgar181 (talk | contribs) at 23:58, 12 April 2018 (image). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Vamorolone
Clinical data
Other namesVB-15; VBP-15; 16α-Methyl-9,11-dehydroprednisolone; 17α,21-Dihydroxy-16α-methylpregna-1,4,9(11)-triene-3,20-dione
Drug classCorticosteroid; Glucocorticoid
Identifiers
  • (8S,10S,13S,14S,16R,17R)-17-Hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.032.874 Edit this at Wikidata
Chemical and physical data
FormulaC22H28O4
Molar mass356.462 g/mol g·mol−1
3D model (JSmol)
  • C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4(C3=CC[C@@]2([C@]1(C(=O)CO)O)C)C
  • InChI=1S/C22H28O4/c1-13-10-18-16-5-4-14-11-15(24)6-8-20(14,2)17(16)7-9-21(18,3)22(13,26)19(25)12-23/h6-8,11,13,16,18,23,26H,4-5,9-10,12H2,1-3H3/t13-,16-,18+,20+,21+,22+/m1/s1
  • Key:ZYTXTXAMMDTYDQ-DGEXFFLYSA-N

Vamorolone (developmental code names VB-15, VBP-15) is a synthetic glucocorticoid corticosteroid which is under development for the treatment of duchenne muscular dystrophy and a number of other conditions.[1][2][3]

References

  1. ^ http://adisinsight.springer.com/drugs/800035994
  2. ^ Guglieri, M.; Clemens, P.; Cnaan, A.; Damsker, J.; Gordish-Dressman, H.; Morgenroth, L.; Davis, R.; Nagaraju, K.; Hathout, Y.; Athanasiou, D.; Vroom, E.; Bushby, K.; Hoffman, E. (2017). "Vision DMD: A drug development program for vamorolone in Duchenne muscular dystrophy". Neuromuscular Disorders. 27: S17. doi:10.1016/S0960-8966(17)30266-3. ISSN 0960-8966.
  3. ^ Wells E, Kambhampati M, Damsker JM, Gordish-Dressman H, Yadavilli S, Becher OJ, Gittens J, Stampar M, Packer RJ, Nazarian J (2017). "Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor". Oncotarget. 8 (6): 9366–9374. doi:10.18632/oncotarget.14070. PMC 5354737. PMID 28030841.

External links